Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dex BTC restrictions?

This article was originally published in The Tan Sheet

Executive Summary

The Army & Air Force Exchange Service has adopted a voluntary plan prohibiting the sale of dextromethorphan (DXM) products to those under the age of 18, the AAFES announces Feb. 9. The policy, enacted Jan. 24, is designed to prevent teenagers from using the drug for recreational purposes. Military members can still purchase DXM products such as Wyeth's Robitussin andAdams' Mucinex over-the-counter at Base Exchange/Post Exchange stores, but will have to show proof of age at check-out. Walgreens enacted a similar nationwide policy in July 2005 in response to an FDA "Talk Paper" highlighting DXM abuse (1"The Tan Sheet" July 4, 2005 p. 12)...

You may also be interested in...



Walgreens Sets Dextromethorphan Age Limit Policy To Curb Abuse

Retailers are working to stay ahead of state legislators looking to place restrictions on products containing the cough suppressant ingredient dextromethorphan (DXM)

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

UsernamePublicRestriction

Register

PS099088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel